الفهرس 
Hepatitis C Virus Infection
FibroTest-ActiTestOnly 14 pages are availabe for public view
 |  | from | 106 |  |  |
| | | from | 106 | | |
Abstract
Hepatitis C virus (HCV) infection is a worldwide disease that affects more than 170 million people, 80% of whom develop chronic hepatitis which may lead to cirrhosis and hepatocellular carcinoma.
For evaluation of the severity of the disease and diagnostic decision-making, liver biopsy remains the golden standard to date. But liver biopsy has many adverse effects, so studies investigating non-invasive alternatives to liver biopsy using biochemical markers have been performed. In 2001, Imbert-Bismuth et al.published a scoring algorithm using a panel of five biochemical markers. α2־macroglobulin, apolipoprotein-Al, haptoglobin, ,γ-glutamyl-transpeptidase (GGT) and total bilirubin for liver fibrosis (Fibrotest) plus alanine aminotransferase (ALAT) for liver inflammatory activity (Actitest).
In the present study we aimed at using the five biochemical markers of Fibrotest as a more reliable testing in assessment of liver cirrhosis, moreover some other biochemical markers of significance were used to see if they could be more reliable than Fibrotest. This was done using the eighty HCV patients divided into two groups; forty non cirrhotic HCV patients. and forty cirrhotic HCV patients. All participants in the study were subjected to full history taking, full clinical examination and laboratory investigations including; aspartate aminotransferase, serum alanine aminotransferase, total bilirubin, serum gamma glutamyl transferase, haptoglobin, α2-macroglobulin and apolipoprotein-Al.
In the current study instead of interpreting the results in the biopredictive laborayory, we used logistic regression equation predicting the patient liver state whether cirrhotic or non-cirrhotic using the same factors used in FibroTest. It equation1 classifies about 86.25 % of the sample cases correctly. In another equation2 a panel of seven serum biochemical markers was used: α2M, Apo-A1, haptoglobin, GGT, ALAT, AST and albumin taking into account the patient’s age. It classifies about 95% of the sample cases correctly. The last equation3 was done using only albumin, Apo-A1 and GGT. This could be used in terms of decreasing the cost of the test and it classifies about 91.25% of the sample cases correctly. It is clear that the second equation2 gives better results than using the first equation1, which means that the markers we chose are more significant than the markers used in FibroTest. Moreover, the last equation3 gives better results than the first equation1 and with less expense.